![\"\"](\"\/hematology\/files\/2021\/04\/Fabio.jpg\")
<\/a>Fabio Petrocca, MD<\/a><\/span><\/strong>\n<\/span>Clinical Associate Professor of Medicine
\nEducation<\/strong>: University of Rome, Sapienza, Italy (MD, 2004)
\nTraining Program: <\/strong>University of Ferrara, Italy (2004-2008)
\nResearch Fellowship<\/strong>: Harvard Medical School and Boston Children’s Hospital (2008-2012)
\nSpecial Interests<\/strong>: Translational and clinical development of CAR T and TCR T cell therapies, Molecular mechanisms of tumor resistance to small molecule targeted agents and cell therapy, Identification and validation of novel cancer therapeutic targets<\/span><\/p>\n
Fabio Petrocca, MD Clinical Associate Professor of Medicine Education: University of Rome, Sapienza, Italy (MD, 2004) Training Program: University of Ferrara, Italy (2004-2008) Research Fellowship: Harvard Medical School and Boston Children’s Hospital (2008-2012) Special Interests: Translational and clinical development of CAR T and TCR T cell therapies, Molecular mechanisms of tumor resistance to small […]<\/p>\n","protected":false},"author":6467,"featured_media":0,"parent":0,"menu_order":25,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/pages\/3247"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/users\/6467"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/comments?post=3247"}],"version-history":[{"count":23,"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/pages\/3247\/revisions"}],"predecessor-version":[{"id":6419,"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/pages\/3247\/revisions\/6419"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/hematology\/wp-json\/wp\/v2\/media?parent=3247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Raphael Szalat, MD, PhD<\/span><\/strong><\/a>
\nDirector, Autologous Stem Cell Transportation Program; Director, Multiple Myeloma Program, Assistant Professor of Medicine
\nEducation<\/strong>: Universite Pierre et Marie Curie Paris VI, Paris, France (MD, 1997-2004)<\/span>
\nResidency<\/strong>: APHP-Assistance Publique des hospitaux de Paris, Paris, France (2004-2010)<\/span>
\nClinical Fellowship<\/strong>: Saint-Louis Hospital, Paris, France (2010-2013)<\/span>
\nFellowship<\/strong>: Boston Medical Center, Boston, MA (2018-2021)<\/span><\/p>\n<\/a>Margaux Dockerty Martin, N.P<\/a><\/strong><\/span>
\nChief APP Lead, Hematology\/Hematologic Malignancies<\/em>
\nAssistant Professor of Medicine
\nEducation<\/strong>: Boston College, Chestnut Hill, MA (2021)<\/p>\n
\nMicaela Rogal, PA-C, MPAS<\/strong><\/span>
\nAssistant Professor of Medicine
\nEducation<\/strong>:Massachusetts College of Pharmacy and Health Science, Manchester, NH (MS, 2024)<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"